Skip to content

A Multicenter, Prospective, Randomized Controlled Study of Oxazepam Combined with Escitalopram for the Treatment of Anxiety Disorders with Depression

A Multicenter, Prospective, Randomized Controlled Study of Oxazepam Combined with Escitalopram for the Treatment of Anxiety Disorders with Depression

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127236
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorder with depression

Interventions

experimental group:Oxazepam combined with escitalopram oxalate Oxazepam, 15–30 mg, PO, q.d.–t.i.d. Escitalopram Oxalate, 10-20mg, PO, q.d.–t.i.d.
Control group:Tandospirone combined with Escitalopram Tandospirone, 10-20m, PO, t.i.d. Escitalopram, 10-20m, PO, q.d.

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18~65 years (including the boundaries), no restriction on gender; 2.Meet the diagnostic criteria for DSM-5 anxiety disorders (including various subtypes such as generalized anxiety disorder, panic disorder, and unspecified anxiety disorder), with a Hamilton Anxiety Scale score >= 14. 3.Has core complaints of depressive symptoms, with a Hamilton-24 Depression Rating Scale score >= 7 points; 4.Voluntarily join the project and sign the informed consent form, and be able to complete the study in accordance with the requirements of the trial protocol;

Exclusion criteria

Exclusion criteria: 1.Patients with major depressive disorder (HAMD-24 >= 24), and those with severe suicidal tendencies (item 3 of HAMD "suicide" >= 3 points); 2.Patients diagnosed with schizophrenia, schizoaffective disorder, delusional disorder, substance dependence, or substance-induced mental disorders, and patients with psychotic symptoms; 3.A history of neurological diseases or major physical illnesses (such as thyroid diseases, systemic lupus erythematosus, lung, liver and kidney damage, infections, major trauma, etc.); 4.Those allergic to oxazepam or escitalopram; 5.Pregnant women, breastfeeding women, or those who plan to have children in the near future; 6.Participants deemed unsuitable for clinical trials by investigators.

Design outcomes

Primary

MeasureTime frame
Change in HAMA total score;HAMA response rate;

Secondary

MeasureTime frame
Change in PSQI score;TESS score;

Countries

China

Contacts

Public ContactYu Haihang

Affiliated Kangning Hospital of Ningbo University

yuhaihang0414@sina.com+86 574 26302520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026